Overview

* Bioventus ( BVS ) Q2 revenue dips 2.4%, organic revenue grows 6.2%

* Adjusted EPS rises 31% to $0.21, beating analyst expectations

* Co reiterates full-year 2025 guidance for revenue, Adjusted EBITDA, and Non-GAAP EPS

Outlook

* Bioventus ( BVS ) reiterates 2025 net sales guidance of $560 mln to $570 mln

* Company expects 2025 adjusted EBITDA of $112 mln to $116 mln

* Bioventus ( BVS ) anticipates 2025 non-GAAP EPS of $0.64 to $0.68

* Company sees tariff impact as immaterial for 2025 guidance

Result Drivers

* DIVESTITURE IMPACT - Revenue decline due to divestiture of Advanced Rehabilitation Business

* ORGANIC GROWTH - Organic revenue rose 6.2% driven by double-digit growth in Surgical Solutions and Restorative Therapies

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Sales Beat $147.70 $145.90

mln mln (4

Analysts

)

Q2 Beat $0.21 $0.2 (3

Adjusted Analysts

EPS )

Q2 $33.80

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Bioventus Inc ( BVS ) is $15.00, about 59.1% above its August 5 closing price of $6.14

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)